STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.
Discover why the Matsato Knife is gaining global recognition in 2025. Explore expert insights, key features, and authentic user experiences behind this precision-crafted Japanese blade.
Discover why the Matsato Knife is gaining global recognition in 2025. Explore expert insights, key features, and authentic user experiences behind this precision-crafted Japanese blade.
Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID